✔Strategy ✔Change Leadership ✔Commercial Innovation ✔Execution ✔Global M&AProven C-level leader with deep experience running global Fortune 500, start-up, and emerging pharmaceutical businesses, possessing the unique ability to blend, build, and strengthen performance from the ground up. Broad understanding of market strategy development within clinically diverse programs that achieve meaningful product differentiation. Significant accomplishments creating profitable business development and investment community partnerships within the C-suite. Strategy/Vision: Deep start-up, transaction and capital raising success through the establishment and guidance of Adiso, Adastra, and Churchill; creation and execution of clinical development and business strategy to lead the companies from formation; with the identification and advancement of multiple first-in-class drug product assets; negotiated and managed lucrative business development partnerships; business development and licensing with Baxalta, transaction to Cothera Bioscience and Sun Pharma FZE.Change Leadership: Adaptable and insightful leader instrumental in the cultural and team transformation of Onconova from a private 16-person medicinal chemistry company into a commercially prepared 67-employee Nasdaq listed company executing a successful Initial Public Offering (IPO). Commercial Innovation: Directly involved in numerous successful product development/co-development programs and commercial launches within oncology and specialty therapeutics. Demonstrated ability to employ unique approaches to value pricing and contracting within competitive markets. Execution/Implementation: Ability to visualize and articulate both long-term and near-term goals while promoting excellence through organization design, leverage of key functional areas, with clear decision making and process application. Global M&A: Marshalled Churchill Pharma through nine-month transaction process and successful sale of assets prior to product approval by FDA, while simultaneously preparing for a Churchill launch. While at Onconova, initiated and negotiated two separate license agreements for Japan/Korea and Europe